Match!
Nishan Rajakumaraswamy
PathologyOncologyAdverse effectColitisChemotherapyMaculopapular rashIdelalisibMedicine
1Publications
0Citations
What is this?
Publications 1
Newest
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
#2Michael J. Pishvaian (JHUSOM: Johns Hopkins University School of Medicine)
view all 5 authors...
LESSONS LEARNED Although this study of idelalisib in patients with PDAC was limited in size and duration because of early termination, idelalisib exposure resulted in an overall safety profile consistent with studies in hematological malignancies, except that the incidences of diarrhea and colitis were reduced in patients with PDAC. Preclinical studies of the PI3K pathway in PDAC and positive clinical results of PI3K inhibition in other cancers support the continued development of PI3K inhibitor...
Source
1